Unfit patients also have the alternative of venetoclax as well as obinutuzumab (VO) as frontline therapy. This relies on a phase III demo that in contrast VO with ClbO in elderly/unfit patients.113 VO was top-quality regarding reaction fee and development-free survival, and experienced a comparable basic safety profile. Within this trial VO was adm